HomeONC • TSE
Follow
Oncolytics Biotech Inc
Previous close
$1.47
Day range
$1.42 - $1.46
Year range
$1.20 - $4.49
Market cap
108.60M CAD
Avg Volume
78.54K
P/E ratio
-
Dividend yield
-
Market news
Financials
Income Statement
Revenue
Net income
(CAD) | Dec 2023info | Y/Y change |
---|---|---|
Revenue | — | — |
Operating expense | 8.85M | 4.01% |
Net income | -3.95M | 53.83% |
Net profit margin | — | — |
Earnings per share | -0.11 | 25.75% |
EBITDA | -8.83M | -4.05% |
Effective tax rate | -1.10% | — |
Balance Sheet
Total assets
Total liabilities
(CAD) | Dec 2023info | Y/Y change |
---|---|---|
Cash and short-term investments | 34.91M | 8.63% |
Total assets | 38.82M | 3.98% |
Total liabilities | 11.26M | 3.92% |
Total equity | 27.56M | — |
Shares outstanding | 75.42M | — |
Price to book | 3.97 | — |
Return on assets | -52.11% | — |
Return on capital | -76.92% | — |
Cash Flow
Net change in cash
(CAD) | Dec 2023info | Y/Y change |
---|---|---|
Net income | -3.95M | 53.83% |
Cash from operations | -6.12M | -3.12% |
Cash from investing | -3.00K | 99.99% |
Cash from financing | 1.74M | -70.32% |
Net change in cash | -5.07M | 75.51% |
Free cash flow | -8.14M | -349.09% |
About
Oncolytics Biotech Inc. is a Canadian company headquartered in Calgary, Alberta, that is developing an intravenously delivered immuno-oncolytic virus called pelareorep for the treatment of solid tumors and hematological malignancies. Pelareorep is a non-pathogenic, proprietary isolate of the unmodified reovirus that: induces selective tumor lysis and promotes an inflamed tumor phenotype through innate and adaptive immune responses. Wikipedia
Founded
1998
Headquarters
Website
Employees
29